{"id":"NCT03713593","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)","officialTitle":"A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-31","primaryCompletion":"2022-06-21","completion":"2024-09-24","firstPosted":"2018-10-22","resultsPosted":"2023-07-24","lastUpdate":"2024-10-10"},"enrollment":794,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"]},{"type":"BIOLOGICAL","name":"pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"saline placebo","otherNames":[]}],"arms":[{"label":"lenvatinib plus pembrolizumab","type":"EXPERIMENTAL"},{"label":"lenvatinib plus placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of advanced hepatocellular carcinoma in adult participants.\n\nThe primary hypotheses of this study are that lenvatinib plus pembrolizumab is superior to lenvatinib plus placebo with respect to progression-free survival (PFS) and overall survival (OS).","primaryOutcome":{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 41 months","effectByArm":[{"arm":"Lenvatinib + Pembrolizumab","deltaMin":8.2,"sd":null},{"arm":"Lenvatinib + Placebo","deltaMin":8.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":26},"locations":{"siteCount":172,"countries":["United States","Australia","Canada","Chile","China","Colombia","France","Germany","Ireland","Italy","Japan","Mexico","New Zealand","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["38039993"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":181,"n":395},"commonTop":["Hypertension","Diarrhoea","Hypothyroidism","Proteinuria","Decreased appetite"]}}